Navigation Links
Althea Technologies Appoints E.J. Brandreth to Vice President of Quality and Regulatory
Date:7/15/2008

SAN DIEGO, July 15 /PRNewswire/ -- Althea Technologies, Inc., a leading provider of innovative technologies and services for pharmaceutical development and manufacturing, announced today that E.J. Brandreth has joined the company as Vice President of Quality and Regulatory. In this role, Mr. Brandreth will be responsible for leading Althea's quality and compliance programs, while overseeing the regulatory support activities, which are required to facilitate the launch of commercial manufacturing services.

(Photo: http://www.newscom.com/cgi-bin/prnh/20020925/LAW010LOGO)

"We are very excited to welcome E.J. Brandreth to Althea. The diverse experience he brings to the company is particularly valuable, as it spans everything from clinical development of innovative products, to the preparation and validation required for commercial launch of successful biopharmaceuticals. His background in clinical and commercial biological products is a perfect fit for the expanding scope of projects at Althea," stated Dr. Magda Marquet, President and Co-CEO of Althea Technologies.

Mr. Brandreth brings over fifteen years of experience in the regulatory and quality assurance fields for the biotechnology and pharmaceutical industries. Prior to joining Althea Technologies, he was Vice President of Quality at Favrille, Inc., where he had oversight of Quality Control, Quality Assurance, Validation and Metrology. In the course of his career he has managed the validation of 11 different biotechnology facilities, and led the Process Validation Programs for five CBER/EMEA product launches. Previous to Favrille, Mr. Brandreth was Senior Director of QA at BioMarin Pharmaceuticals, Inc. where he supported a variety of clinical products and launched two commercial products. Prior to that, he held management positions in QA, Validation and Regulatory Affairs at IDEC Pharmaceuticals, where he assisted in the development and launch of Zevalin(R) and Rituxan(R), CBER's first approved monoclonal antibody for cancer. Additionally, Mr. Brandreth has helped to develop two Parenteral Drug Association (PDA) technical reports.

E.J. Brandreth added, "I am very pleased to join the outstanding team of professionals here at Althea Technologies. I've watched the company's growth and I am really happy that I can call upon my experience to help assure the quality, compliance and facility validation efforts underway, which will best serve Althea's clients. I'm joining Althea as the activities focused upon the release of the newly constructed state-of-the-art commercial-scale facility head into high gear, so I will be able to jump right in as we write this exciting new chapter in the company's history."

About Althea Technologies, Inc.

Althea Technologies, a leading San Diego-based pharmaceutical services firm, provides critical manufacturing services that support researchers worldwide in their advancement of novel therapies and efforts to apply new genomic information. Althea's services include cGMP contract manufacturing of recombinant proteins, DNA-based therapeutics and vaccines, and aseptic filling. For more information, visit http://www.altheatech.com.


'/>"/>
SOURCE Althea Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
2. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
3. VNUS Medical Technologies Announces Resignation of Chief Financial Officer and VP, Finance & Administration
4. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
5. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
6. Advanced technologies aim to transform the coaching of top athletes
7. Global Med Technologies(R) Extends Its Worldwide Outreach
8. Acuo Technologies(R) Names Mike Dolan Vice President of Sales
9. ReBuilder Medical Technologies, Inc. Signs Agreement for Distribution in Maine
10. Neurobiological Technologies Reports Going Concern Qualification
11. MedCom USAs Subsidiary Card Activation Technologies, Inc.s SB2 Registration Declared Effective by SEC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... TherapySites, the leading website and ... Tennessee Counseling Association. This new relationship allows TherapySites to continue to extend ... exclusive benefits and promotional offers. , "TCA is extremely excited about this new ...
(Date:6/26/2016)... PLAINSBORO, N.J. (PRWEB) , ... June 27, 2016 , ... ... same sources, yet in many ways they remain in the eye of the beholder, ... Oncology (EBO), a publication of The American Journal of Managed Care. For the full ...
(Date:6/26/2016)... ... 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to ... app. The fitness app plans to fix the two major problems leading the fitness industry ... fits all type program , They don’t eliminate all the reasons people quit ...
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... their offering. The current ... environment for MedImmune to enter. The US ageing population creates ... drive considerable growth for effective anti-influenza medications. The introduction of ... but development is still in its infancy. ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
Breaking Medicine Technology: